Design of Reach: Phase 3 randomized, double-blind, placebo-controlled, 48-week study of the efficacy and safety of losmapimod in FSHD

R. Tawil; J. Han; L. Wang; J. Vissing; B. van Engelen; J. Statland; M. Mellion; J. Shoskes; C. Morabito; J. Jiang; J. Webster

doi:10.1016/j.nmd.2022.07.258

Design of Reach: Phase 3 randomized, double-blind, placebo-controlled, 48-week study of the efficacy and safety of losmapimod in FSHD

R. Tawil, J. Han, L. Wang, J. Vissing, B. van Engelen, J. Statland, M. Mellion, J. Shoskes, C. Morabito, J. Jiang, J. Webster

Research output: Contribution to journal › Conference abstract in journal › Research › peer-review

Original language	English
Article number	P.136
Journal	Neuromuscular Disorders
Volume	32
Issue number	Supplement 1
Pages (from-to)	S104-S104
Number of pages	1
ISSN	0960-8966
DOIs	https://doi.org/10.1016/j.nmd.2022.07.258
Publication status	Published - 2022
Event	27th International Congress of the World-Muscle-Society (WMS) - Halifax, Canada Duration: 11 Oct 2022 → 15 Oct 2022

Conference

Conference	27th International Congress of the World-Muscle-Society (WMS)
Country/Territory	Canada
City	Halifax
Period	11/10/2022 → 15/10/2022

Access to Document

10.1016/j.nmd.2022.07.258

Cite this

Tawil, R., Han, J., Wang, L., Vissing, J., van Engelen, B., Statland, J., Mellion, M., Shoskes, J., Morabito, C., Jiang, J., & Webster, J. (2022). Design of Reach: Phase 3 randomized, double-blind, placebo-controlled, 48-week study of the efficacy and safety of losmapimod in FSHD. Neuromuscular Disorders, 32(Supplement 1), S104-S104. [P.136 ]. https://doi.org/10.1016/j.nmd.2022.07.258

Design of Reach : Phase 3 randomized, double-blind, placebo-controlled, 48-week study of the efficacy and safety of losmapimod in FSHD. / Tawil, R.; Han, J.; Wang, L.; Vissing, J.; van Engelen, B.; Statland, J.; Mellion, M.; Shoskes, J.; Morabito, C.; Jiang, J.; Webster, J.

In: Neuromuscular Disorders, Vol. 32, No. Supplement 1, P.136 , 2022, p. S104-S104.

Research output: Contribution to journal › Conference abstract in journal › Research › peer-review

Tawil, R, Han, J, Wang, L, Vissing, J, van Engelen, B, Statland, J, Mellion, M, Shoskes, J, Morabito, C, Jiang, J & Webster, J 2022, 'Design of Reach: Phase 3 randomized, double-blind, placebo-controlled, 48-week study of the efficacy and safety of losmapimod in FSHD', Neuromuscular Disorders, vol. 32, no. Supplement 1, P.136 , pp. S104-S104. https://doi.org/10.1016/j.nmd.2022.07.258

@article{9cb316a3db884cf5b7dcddf6a1804daa,

title = "Design of Reach: Phase 3 randomized, double-blind, placebo-controlled, 48-week study of the efficacy and safety of losmapimod in FSHD",

author = "R. Tawil and J. Han and L. Wang and J. Vissing and {van Engelen}, B. and J. Statland and M. Mellion and J. Shoskes and C. Morabito and J. Jiang and J. Webster",

year = "2022",

doi = "10.1016/j.nmd.2022.07.258",

language = "English",

volume = "32",

pages = "S104--S104",

journal = "Journal of Neuromuscular Diseases",

issn = "0960-8966",

publisher = "Elsevier",

number = "Supplement 1",

note = "27th International Congress of the World-Muscle-Society (WMS) ; Conference date: 11-10-2022 Through 15-10-2022",

}

TY - ABST

T1 - Design of Reach

T2 - 27th International Congress of the World-Muscle-Society (WMS)

AU - Tawil, R.

AU - Han, J.

AU - Wang, L.

AU - Vissing, J.

AU - van Engelen, B.

AU - Statland, J.

AU - Mellion, M.

AU - Shoskes, J.

AU - Morabito, C.

AU - Jiang, J.

AU - Webster, J.

PY - 2022

Y1 - 2022

U2 - 10.1016/j.nmd.2022.07.258

DO - 10.1016/j.nmd.2022.07.258

M3 - Conference abstract in journal

VL - 32

SP - S104-S104

JO - Journal of Neuromuscular Diseases

JF - Journal of Neuromuscular Diseases

SN - 0960-8966

IS - Supplement 1

M1 - P.136

Y2 - 11 October 2022 through 15 October 2022

ER -